



## Research Article

## THE STUDY ON THE EFFICACY OF *SUKOSHNA* (LUKE WARM) *YASHTIMADHU GHRITA* IN THE MANAGEMENT OF PAIN DURING APPLICATION OF *KSHARASUTRA* IN *BHAGANDARA* (FISTULA IN ANO)

Sri Jyothsna P M<sup>1\*</sup>, S.Dattatreya Rao<sup>2</sup>, T.Udaya Kiran<sup>3</sup>

<sup>1</sup>Lecturer, Sri Madakari Nayaka Ayurvedic Medical College and Hospital, Karnataka, India.

<sup>2</sup>Professor & HOD, <sup>3</sup>Reader, Dept of Shalya, S.V Ayurvedic College, Tirupati, AP., India.

**KEYWORDS:** *Bhagandara*, *Ashta Mahagadas*, *Apamarga Ksharasutra*, *Sukoshna* (Luke warm) *Yashtimadhu Ghrita*, Xylocaine Jelly, Anaesthetic, Non-invasive, Shooting and Scalding Pain.

### ABSTRACT

*Bhagandara* is one of the oldest diseases which have been described as one of the *Ashta Mahagadas* (Eight grave disorders). *Ksharasutra* application is a successful method and is one of the chief modalities described for the treatment of *Bhagandara* in *Ayurvedic* texts. The local cauterizing pain and prolonged period of treatment causes the agony in few patients and make them to avoid undergoing *Ksharasutra* application. The ability to alleviate pain is one of the most noteworthy goals during change of *Ksharasutra* in *Bhagandara*. The conventional use of 2% xylocaine jelly before changing *Ksharasutra* had local anaesthetic effect up to limited time and also didn't have any other advantages like healing of fistula. 30 patients with signs and symptoms of *Bhagandara* who are treated with *Ksharasutra* were selected by simple random sampling method. *Apamarga Ksharasutra* and *Yastimadhu Ghrita* were prepared as per the standard method described in *Ayurvedic* texts. In the present trial 4 sittings were taken into study and in the 1<sup>st</sup> sitting 2% xylocaine jelly was applied and in the next three sittings, *Sukoshna* (Luke warm) *Yastimadhu Ghrita* was applied to find out its effectiveness in the management of pain during *Ksharasutra* therapy by comparing 1<sup>st</sup> and Last sitting. Lastly, it was concluded that the present study was efficacious and non-invasive and it was found to be statistically highly significant in alleviating pain, burning sensation and PRD during and after application of *Ksharasutra* without any side effect.

### \*Address for correspondence

Dr Sri Jyothsna P M

PG Scholar,

Dept of Shalya,

S.V Ayurvedic College, Tirupati,  
AP., India.

Email: [sri.josh8@gmail.com](mailto:sri.josh8@gmail.com)

Contact: 9490728990

### INTRODUCTION

*Ayurveda* the ancient and holistic system of Indian Medicine consists of *Ashtangas*<sup>[1]</sup> and *Shalyatantra* (surgery) which is one among them<sup>[2]</sup> has been mentioned best of all branches. The disease *Bhagandara* analogous to Fistula-in-ano in the modern surgical terms has been considered under the *Ashta Mahagadas*.<sup>[3]</sup> The continuous discharge and soiling of the clothes is an essential factor of the disease process and is responsible for the restlessness of the sufferer.

It leads to a stage where physical, psychological and social equilibrium is disturbed. In Modern surgery, this problem is known for its callus nature to get cured and for its high recurrence rate.

According to a recent study conducted by Sainio P. on the prevalence rate of fistula in ano in a

London based Hospital Male: Female = 1.8: 1, Mean age of patient is 38.3 years<sup>[4]</sup>. Surgical treatment of fistula-in-ano required hospitalization with a significant risk of recurrence in 0.7% - 26.5% and high risk of impaired continence in 5% - 40% of patients.<sup>[5]</sup>

*Ksharasutra* therapy which is one of the chief modalities described for the treatment of *Bhagandara* in *Ayurvedic* texts<sup>[6]</sup>. Now days, *Ksharasutra* is the first choice for treating fistula in ano.

### AIMS & OBJECTIVES OF THE STUDY

- The main aim of this study was to evaluate the efficacy of *Sukoshna* (Luke warm) *Yashtimadhu*

*Ghrita* during change of *Ksharasutra* for the management of pain in *Bhagandara*.

- The objective of the present study was to formulate a procedure for alleviation of pain and burning sensation which was major hurdle in *Ksharasutra* therapy.

### Importance and Need of Present Study

So far no work was done on management of pain in patients of fistula undergoing *Ksharasutra* application. Hence, to find out an alternative to conventional change of *Ksharasutra* by 2% xylocaine jelly and better pain alleviating feature, *Sukoshna* (Luke warm) *Yashtimadhu Ghrita* was opted for clinical evaluation.

### Selection of Drug

In the present clinical study *Sukoshna* (Luke warm) *Yashtimadhu Ghrita* was applied into the fistulous track in fistula patients during the change of *Ksharasutra*. The idea of this study is taken from *Agropaharaneeyaadhya* of *Susruta Samhita*<sup>[7]</sup>. *Yashtimadhu* has *Vedanasthapana*, *sothahara* and *Vranaropana* properties<sup>[8]</sup>. Probably application of *Ghrita* externally relieves pain & burning sensation in fistula as it has *Soolahara*, *Vranaropana* and *Sodhana* properties. The application of *Ghrita* in luke warm state helps in decongesting the fistulous track and lubricates it. Keeping in mind of such advantage it has been planned to use Luke warm *Ghrita* in present study.

### MATERIALS AND METHODS

**Materials:** *Yastimadhughrita* and *Apamarga Ksharasutra*.

Ingredients required for the preparation of *Yastimadhu ghrita*.

- Dried roots of *Yashtimadhu*
- Go-Ghrita*

*Apamargaksharasutra* was prepared as per the standard method described in Ayurvedic texts<sup>[9,10]</sup>.

**Method of Preparation of drug** was done under aseptic conditions according to *Ghritapaaka* explained in *Sarangadhara samhita*, *Madhyama khanda*<sup>[11]</sup>. *Yastimadhu* roots *Kalka* (paste), *Go Ghrita* and *Kashayam* of roots (decoction) was taken in a ratio of 1:4:16. This combination was kept in a big vessel and heated up on a mild fire till the water and moisture content of the mixture is completely evaporated. The continues stirring was done and the stage of *Phenasanthi*. The prepared *Ghrita* was continuously heated till it attains *Kharapaka* and it was filtered and collected in a glass jar.

**Selection of Patients:** Patients were selected by simple random sampling method, from the IPD and OPD.

### Methods

**Design of the study** – It was a Randomised Single Blind Study

**Place of the study** - Department of *Shalya Tantra*, S.V.Ayurvedic College and Hospital, Tirupati.

**Sample size:** 30 patients

### Criteria for selection of cases

Patient with signs and symptoms of *Bhagandara* who are treated with *Ksharasutra* are taken for the present study on the basis of the following inclusion and exclusion criteria.

### Inclusion criteria

- Diagnosed cases of *Bhagandara* operated by the method of *Ksharasutra* application.
- Age group of 20 -70 years.
- Patients of either sex were selected.

### Exclusion criteria

- Patients suffering with uncontrolled Diabetes Mellitus and Hypertension and patients with immune compromised conditions.
- Fistulae developing secondary to diseases like Tuberculosis, Chronic or acute ulcerative colitis, Crohn's disease, Malignancies etc.

### Consent

Patients were well informed about the pros and cons of the treatment and signature on the informed consent form was taken from the patient.

### Plan of the study

The clinical study is carried out in 3 phases

### Phase - I

All the 30 collected patients who were fit for the selection criteria were selected for the study.

**Phase -II** For every patient 4 sittings of trial i.e., change of *Ksharasutra* after application of the specially prepared *Yashtimadhu Ghrita* or xylocaine jelly are undertaken.

**Phase -III** Evaluation of clinical data which was collected and recorded

### Administration Procedure

#### a. Sittings of the trial

**1<sup>st</sup> Sitting:** Conventional method of change of *Ksharasutra* without application of trial drug will be taken up and the patient will be asked for his severity of pain felt and report on the 10 point analog scale designed for the study to assess the quantum of pain during the procedure of change of *Ksharasutra* so as

to compare with the pain elicited in subsequent sittings when trial drug is applied.

**2<sup>nd</sup> Sitting:** 5 to 10ml of *Sukoshna* (luke warm) *Yashtimadhu ghrita* will be irrigated before 30min of *Ksharasutra* application and the pain felt during the change is recorded on 10 point analog scale and to be compared with the score elicited in first sitting (xylocaine).

**3<sup>rd</sup> Sitting:** 5 to 10ml of *Sukoshna* (Luke warm) *Yashtimadhu Ghrita* will be irrigated before 20min of *Ksharasutra* application and the pain felt during the change is recorded on 10 point analog scale and to be compared with the score elicited in second sitting.

**4<sup>th</sup> Sitting:** 5 to 10ml of *Sukoshna* (Luke warm) *Yashtimadhu Ghrita* will be irrigated before 10min of *Ksharasutra* application and the pain felt during the change is recorded on 10 point analog scale and to be compared with the score elicited in third sitting.

**b. Post Application Procedure**

Patients were advised to take sitz bath twice daily. All the patients were advised to take light, easy digestible and non-spicy food.

**Duration of the treatment:** 4 weeks continuously after undergoing surgery for *Ksharasutra* application

**Assessment Criteria**

**Subjective Parameters**

**Pain**

- Intensity of pain (0-10)
- Duration of pain

**Burning Sensation**

- Intensity of burning sensation(0-10)
- Duration of burning sensation

Intensity of pain and Intensity of burning sensation was recorded on 10 point Analog scale according to the patient's self assessment criteria.

Duration of pain and Duration of burning sensation after *Ksharasutra* change was recorded according to the patient's self assessment criteria.

**Pain relief day (P.R.D):** This is the day when the patient is totally relived or free from post procedural pain.

**Objective Parameters**

**Unit Cutting Time**

= **Total No. of days taken to cut through the tract**

**Initial length of the *Ksharasutra* in cms**

**Table 7: Type of *Bhagandara* in the patients**

| Type of <i>Bhagandhara</i> | No. of patients | %     |
|----------------------------|-----------------|-------|
| <i>Sataponaka</i>          | 3               | 10    |
| <i>Ustragriva</i>          | 5               | 16.66 |
| <i>Parisravi</i>           | 20              | 66.66 |
| <i>Sambukavarta</i>        | 0               | 0     |
| <i>Unmargi</i>             | 2               | 6.66  |

This is recorded as per routine, to know the general condition and effect of trial on cutting.

**OBSERVATIONS**

The present study reveals that the incidence of *Bhagandara* is more among male patients, with mixed diet, mainly of *Vata pitta prakriti*, most of the patients are with pus discharge and pain with gradual onset, 0-12 months chronicity, 6-8cms initial length of tract, *Parisravi* type of *Bhagandara* and low anal type of *Fistula*.

**Table 1: Sex wise distribution of patients**

| Sex    | No. of patients | %  |
|--------|-----------------|----|
| Male   | 27              | 90 |
| Female | 3               | 10 |

**Table 2: Diet habit of patients**

| Diet       | No. of patients | %     |
|------------|-----------------|-------|
| Vegetarian | 2               | 6.66  |
| Mixed      | 28              | 93.33 |

**Table 3: *Prakriti* wise distribution of patients**

| Types of <i>Prakriti</i> | No. of patients | %     |
|--------------------------|-----------------|-------|
| <i>Vata Pitta</i>        | 12              | 40    |
| <i>Pitta Kapha</i>       | 11              | 36.66 |
| <i>Vata Kapha</i>        | 7               | 23.33 |

**Table 4: Chief complaints of patients**

| Chief Complaints  | No of Patients | %     |
|-------------------|----------------|-------|
| Discharge         | 28             | 93.33 |
| Pain              | 27             | 90    |
| Induration        | 18             | 60    |
| Burning Sensation | 14             | 46.66 |
| Itching           | 9              | 30    |
| Tenderness        | 8              | 26.66 |

**Table 5: Chronicity of the disease in the patients**

| Chronicity of disease in months | No. of patients | %     |
|---------------------------------|-----------------|-------|
| 0-12                            | 20              | 66.66 |
| 13-24                           | 10              | 33.33 |
| 25-36                           | 0               | 0     |
| 37-48                           | 0               | 0     |

**Table 6: Initial length of the tract in cms**

| Initial length | No. of patients | %     |
|----------------|-----------------|-------|
| 0-2cms         | 0               | 0     |
| 2-4cms         | 1               | 3.33  |
| 4-6cms         | 8               | 26.66 |
| 6-8cms         | 11              | 36.66 |
| 8-10cms        | 7               | 23.33 |
| 10-12cms       | 3               | 10    |

**Table 8: Type of Fistula in the patients**

| Type of fistula         | No. of patients | %     |
|-------------------------|-----------------|-------|
| Submucosal/Subcutaneous | 5               | 16.66 |
| Low Anal                | 21              | 70    |
| High Anal               | 4               | 13.33 |

**Table 9: Showing mean of subjective and objective parameters in all the sittings among all the patients**

| Mean of parameter              | 1 <sup>st</sup> sitting | 2 <sup>nd</sup> sitting | 3 <sup>rd</sup> sitting | 4 <sup>th</sup> sitting |
|--------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Intensity of Pain              | 10                      | 7.767                   | 5.867                   | 4.46                    |
| Intensity of burning sensation | 10                      | 7.567                   | 5.6                     | 4.167                   |
| PRD                            | 2.5                     | 1.51                    | 0.95                    | 0.78                    |

**Table 10: Showing mean of subjective parameters in 1<sup>st</sup> and 4<sup>th</sup> sitting among all the patients**

| Mean of parameter             | 1 <sup>st</sup> sitting | 4 <sup>th</sup> sitting |
|-------------------------------|-------------------------|-------------------------|
| Duration of pain              | 39.266                  | 4.033                   |
| Duration of burning sensation | 5.833                   | 1.741                   |

#### Comparison of Average UCT of present study with earlier works

- Present study - 7.09 days
- Deshpande et al - 6 to 7 days
- Dattatreya Rao et al - 4.46 days

The UCT was also studied and compared with earlier research works which shows no interference of present trial procedure with the UCT.

**Table 11: Showing Average UCT according to type of Fistula**

| Type of fistula         | Average UCT |
|-------------------------|-------------|
| Submucosal/Subcutaneous | 7.6         |
| Low Anal                | 7.06        |
| High Anal               | 6.57        |

**Table 12: Showing Average PRD (in days) according to type of Fistula**

| Type of fistula          | Average PRD |
|--------------------------|-------------|
| Submucosal/ Subcutaneous | 1.25        |
| Low Anal                 | 1.44        |
| High Anal                | 1.46        |

## RESULTS

### Statistical Analysis

The parameters are subjected for statistical analysis of Paired t test and One way anova with multiple comparisons at 1% level of significance. All the subjective and objective parameters were found to be highly significant with significant difference between 1<sup>st</sup> sitting with baseline conventional method of thread change and 4<sup>th</sup> sitting with irrigation of *Sukoshnayashtimadhughrita* 10min before change of *Ksharasutra* with 55.33%, 58.4%, 89.73%, 70.15% and 68% of relief for intensity of pain, intensity of burning sensation, duration of pain, duration of burning sensation and PRD respectively.

### Subjective Parameters

#### Intensity of pain

**Table 13: Showing one way anova test for intensity of pain**

| Source of variance | SS    | df | M S     | F value  |
|--------------------|-------|----|---------|----------|
| Between Groups     | 518.6 | 3  | 172.9   | 3.847*** |
| Within Groups      | 100.2 | 29 | 3.454   |          |
| Total              | 618.8 | 32 | 176.354 |          |

**Table 14: Showing one way anova multiple comparisons for intensity of pain**

| Comparison  | A <sub>1</sub> vs B <sub>1</sub> | A <sub>1</sub> vs C <sub>1</sub> | A <sub>1</sub> vs D <sub>1</sub> |
|-------------|----------------------------------|----------------------------------|----------------------------------|
| M.D.        | 2.233                            | 4.133                            | 5.533                            |
| S.E of diff | 0.2699                           | 0.2432                           | 0.2701                           |
| % of relief | 22.33%                           | 41.33%                           | 55.33%                           |

**Intensity of burning sensation**

**Table 15: Showing one way anova test for intensity of burning sensation**

| Source of variance | SS    | df | M S     | F value  |
|--------------------|-------|----|---------|----------|
| Between Groups     | 575.9 | 3  | 192     | 3.953*** |
| Within Groups      | 106.2 | 29 | 3.661   |          |
| Total              | 682.1 | 32 | 195.661 |          |

**Table 16: Showing one way anova multiple comparisons for intensity of burning sensation**

| Comparison  | A <sub>2</sub> vs B <sub>2</sub> | A <sub>2</sub> vs C <sub>2</sub> | A <sub>2</sub> vs D <sub>2</sub> |
|-------------|----------------------------------|----------------------------------|----------------------------------|
| M.D.        | 2.433                            | 4.4                              | 5.833                            |
| S.E of diff | 0.2568                           | 0.2519                           | 0.292                            |
| % of relief | 24.34%                           | 44%                              | 58.4%                            |

**Table 17: Showing paired two sample t test for subjective parameters**

| Parameter                     | 1st sitting | 4th sitting | % Relief | Mean  | S.D.  | S.E.  | 't'   | P        | Inference |
|-------------------------------|-------------|-------------|----------|-------|-------|-------|-------|----------|-----------|
| Duration of pain              | 39.26       | 4.03        | 89.73%   | 35.23 | 30.98 | 5.657 | 6.229 | < 0.0001 | ***       |
| Duration of burning sensation | 5.83        | 1.74        | 70.15%   | 4.100 | 2.589 | 0.472 | 8.675 | < 0.0001 | ***       |

**OBJECTIVE PARAMETER**

**Pain Relief Day (PRD)**

**Table 18: Showing one way anova test for PRD**

| Source of variance | SS    | df | M S     | F value  |
|--------------------|-------|----|---------|----------|
| Between Groups     | 54.68 | 3  | 18.23   | 3.352*** |
| Within Groups      | 13.34 | 29 | 0.4601  |          |
| Total              | 68.02 | 32 | 18.6901 |          |

**Table 19: Showing one way anova multiple comparisons for PRD**

| Comparison  | A <sub>3</sub> vs B <sub>3</sub> | A <sub>3</sub> vs C <sub>3</sub> | A <sub>3</sub> vs D <sub>3</sub> |
|-------------|----------------------------------|----------------------------------|----------------------------------|
| M.D.        | 0.9833                           | 1.55                             | 1.733                            |
| S.E of diff | 0.09123                          | 0.1299                           | 0.1285                           |
| % of relief | 39.6%                            | 62%                              | 68%                              |

**Note:** \*\*\* Highly significant

**Overall effect of Therapy**

Overall effect of therapy shows that there is good response in 56.66% patients, moderate response in 43.33% patients and nil percentage of patients were seen under poor response and no response categories

**Table 20: Overall effect of Therapy**

| Relief            | No. of patients | % of patients |
|-------------------|-----------------|---------------|
| Good response     | 17              | 56.66%        |
| Moderate response | 13              | 43.33%        |
| Poor response     | 0               | 0%            |
| No response       | 0               | 0%            |

## UNTOWARD or SIDE EFFECTS

No side effects were observed during the course of the study.

**Fig No 1 - 4 Showing before and during treatment of present trial (Pt No. SJ0802)**



**Pic 1: Before Change of Ksharasutra**



**Pic 2: During change of Ksharasutra**

**Pt No. SJ0330**



**Pic 3: Before Change of Ksharasutra**



**Pic 4: During change of Ksharasutra**

## DISCUSSION

All the parameters were subjected to statistical analysis of one way anova multiple comparison test and paired t test and were found to be highly significant with significant difference between 1<sup>st</sup> sitting and 4<sup>th</sup> sitting with 55.33%, 58.4%, 89.73%, 70.15% and 68% of relief for intensity of pain, intensity of burning sensation, duration of pain, duration of burning sensation and PRD respectively. The UCT was also studied and compared with earlier research works and was inferred that the procedure of the *Sukoshna* (Luke warm) *Yashtimadhu Ghrita* application does not interfere with the UCT of the fistula patients undergoing *Ksharasutra* treatment. In this clinical study it is observed that there is good response in 56.66% patients, moderate response in 43.33% patients and no patient is under poor response and no response categories.

### **Probable mode of action of *Yashtimadhu Ghrita***

Probably the trial drug may work as TRPV1 antagonist on the cell membrane and may block the transduction channel of the receptors of pain

sensation in the lining membrane of the fistulous tract because of flavonoids and isoflavonoids<sup>[12]</sup> present in the dried roots of *Yashtimadhu* which was proved by earlier study on *Anthocephalus chinensis* (Lam)<sup>[13]</sup>. Further the inclusion of luke warm *Ghrita* which facilitates the penetration of the drug in to the deeper planes of the lining membrane and underneath tissue may enhance the action of *Yashtimadhu*. Thus the comprehensive overall action of *Yashtimadhu* as pain controlling agent can be understood.

The presence of *Vatapittahara* and *Vedana-sthapana*<sup>[8]</sup>, analgesic and anti-inflammatory<sup>[12]</sup> properties in *Yashtimadhu* and the presence of *Vatapittahara*, *Soolahara*<sup>[14]</sup> and sedative<sup>[15]</sup> properties in *Ghrita* may have helped the trial drug in alleviating pain and burning sensation. The advantage of *Vranaropana* and *Vranasodhana* properties in *Yashtimadhu* and *Ghrita* will enhance the efficacy of drug not only in relieving the pain and burning sensation but also healing of the wound.

**CONCLUSION**

In the disease *Bhagandara* (Fistula in ano) the pain felt by the patient during *Ksharasutra* maneuvers was the prime thrust area for the present research work. The application of *Sukoshna Yashtimadhu Ghrita* was found to be significantly efficacious in alleviating pain, burning sensation and PRD during and after the maneuvers with *Ksharasutra*.

Though the limitations of the study are manifold but it is a beginning in a right direction to establish in perfect way of pain control during the *Ksharasutra* therapy with the indigenous drugs and procedures. It is recommended to start a bigger study to pave the way for active analgesia through indigenous techniques.

**REFERENCES**

1. Sastri A., editor. *Susruta Samhita of Vriddha Susruta*, Vol-1, Sutrasthan-1, verse no- 6, Varanasi, Chaukhambha Sanskrit Sansthan, 2010 edition, p.5.
2. Sastri A., editor. *Susruta Samhita of Vriddha Susruta*, Vol-1, Sutrasthan-1, verse no- 7, p.5.
3. Sastri A., editor. *Susruta Samhita of Vriddha Susruta*, Vol-1, Sutrasthan-33, verse no- 4, p.163.
4. Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological aspects. *Ann Chir Gynaecol.* 1984; 73 (4):219-24.
5. Garcia-Aguilar j, Belmonte C, Wong WD, Goldberg SM, Madoff RD. Anal fistula surgery: factors associated with recurrence and incontinence *Dis Colon Rectum* 1996; 39:723-9.
6. Sastri A., editor. *Susruta Samhita of Vriddha Susruta*, Vol-1, Cikitsasthana-17, verse no- 32, p.101.
7. Sastri A., editor. *Susruta Samhita of Vriddha Susruta*, Vol-1, Sutrasthan-5, verse no- 42, p.27.
8. Misra Band Vaisya R., editors. *Bhavaprakasa Samhita of Bhavamisra*, 11<sup>th</sup> edition, Chaukhambha Sanskrit Sansthan, Varanasi, 2010, Vol-1, verse no-146, p.65..
9. Tripathi J .P. Chakrapanidatta's, Chakradatta, Hindi commentary *Bhavarthasandipini* , chapter no- 5, slok no-148, Varanasi, Chaukhambha Sanskrit Series, 1983 Edition, P.91.
10. *The Ayurvedic Pharmacopoeia of India*, Part 2, volume 2, chapter 51.
11. K.R. Srikantha Murthy., English translator. *Sarngadhara Samhita of Sarngadhara*, Madhyama khand- 9, verse no-1, Varanasi, Chaukhambha Orientalia, 2011 edition, p.115.
12. Asha Roshan et al., Phytochemical constituent, Pharmacological activities and medicinal uses through the mellenia of *glycyrrhiza glabra* linn: A Review, *IRJP* 2012,3(8). Available from: [http://www.irjponline.com/admin/php/uploads/1284\\_pdf.pdf](http://www.irjponline.com/admin/php/uploads/1284_pdf.pdf)
13. Dodoala Sujatha et al., Amelioration of chronic pain by *Anthocephalus chinensis* (Lam) extract is mediated through TRPV1 receptors, NIPER, Hyderabad, India. Available from: [https://bps.conference-services.net/resources/344/3811/pdf/Pharm14\\_0227.pdf](https://bps.conference-services.net/resources/344/3811/pdf/Pharm14_0227.pdf)
14. Sastri A., editor. *Susruta Samhita of Vriddha Susruta*, Vol-1, Sutrasthan-45, verse no- 96,97, p.228.
15. Achliya GS, Wadodkar SG, Dorle AK. Evaluation of sedative and anticonvulsant activities of *Unmadnashak Ghrita*. *J Ethnopharmacol.* 2004; 94:77-83.

**Cite this article as:**

Sri Jyothsna P M, S.Dattatreya Rao, T.Udaya Kiran. The Study on the Efficacy of *Sukoshna* (Luke Warm) *Yashtimadhu Ghrita* in the Management of Pain During Application of *Ksharasutra* in *Bhagandara* (Fistula in Ano). *AYUSHDHARA*, 2017;4(5):1338-1344.

Disclaimer: AYUSHDHARA is solely owned by Mahadev Publications - A non-profit publications, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. AYUSHDHARA cannot accept any responsibility or liability for the articles content which are published. The views expressed in articles by our contributing authors are not necessarily those of AYUSHDHARA editor or editorial board members.